Results 201 to 210 of about 69,031,262 (351)

Diagnostic Testing and Treatment Guidelines for COVID-19 and Influenza [PDF]

open access: yes
Thursday, February 1, 2024Diagnostic testing for SARS-CoV-2 and influenza viruses can guide clinical management, including appropriate antiviral treatment, particularly in persons at higher risk for progression to severe disease from COVID-19 and ...

core  

Immune Checkpoint Inhibitor as a Fifth Component of Lipid Nanoparticles Enables Lymph Node‐Targeting and Augments mRNA Vaccine Efficacy

open access: yesAdvanced Science, EarlyView.
Here, a PDL1 inhibitor is employed as a fifth component to modify lipid nanoparticles (LNPs). PDL1 inhibitor‐loaded LNPs show enhanced lymph node targeting, resulting in greater lymph node expansion, immune cell infiltration, and improved mRNA vaccine efficacy. This fifth component LNP could be a novel platform for mRNA vaccines.
Minki Ha   +5 more
wiley   +1 more source

COVID-19 Disease and Treatment of COVID-19 [PDF]

open access: yesBiomedical Journal of Scientific & Technical Research, 2021
openaire   +1 more source

Sarbecoviruses Suppress Innate Immunity by Recruiting PPM1A to Modulate STAT2 and ORF9b Phosphorylation

open access: yesAdvanced Science, EarlyView.
Sarbecovirus ORF9b recruits host phosphatase PPM1A to suppress innate immunity through dual mechanisms. PPM1A directly dephosphorylates ORF9b to sustain its activity and indirectly downregulates STAT2 phosphorylation to impair interferon signaling. Pharmacological inhibition of PPM1A restores antiviral responses and limits sarbecovirus replication ...
Lixiang Xie   +24 more
wiley   +1 more source

Porphyrin‐Based Porous Materials for Antibacterial Applications

open access: yesAdvanced Science, EarlyView.
Porphyrin‐based porous materials have excellent photophysical properties and tunable structures for high‐efficiency antibacterial therapy. This review comprehensively discusses the structural design strategies and synthetic pathways of the four main types of porphyrin‐based porous materials, summarizes their cross‐domain antimicrobial applications, and
Xiao‐Xue Liang   +4 more
wiley   +1 more source

An Oral Antiviral Combination Against Severe COVID‐19 Enabled by the Synergistic Mechanisms of Action of Auranofin and Remdesivir

open access: yesAdvanced Science, EarlyView.
FDA‐approved anti‐inflammatory drug Auranofin inhibits SARS‐CoV‐2 replication by inhibiting viral Main protease activity and Spike processing required for viral entry. It shows strong synergy with nucleoside analogue Remdesivir, due to non‐overlapping mechanisms.
Oyahida Khatun   +13 more
wiley   +1 more source

Symptom‐Driven Prediction of Chronic Multimorbidity with a Macro–Micro Heterogeneous Graph Neural Network

open access: yesAdvanced Science, EarlyView.
Clinical symptoms offer a window into multimorbidity. A macro‐micro heterogeneous graph neural network integrates clinical records with biomedical knowledge to improve patient‐level symptom‐disease association learning and visit‐level multimorbidity completion.
Yiheng Ye   +15 more
wiley   +1 more source

Cost‐Effective Ti/Al/Ni Multilayer Neural Probes With In Vivo Recording Performance Comparable to Ti/Au Neural Probes

open access: yesAdvanced Electronic Materials, EarlyView.
In this study, we developed a cost‐efficient neural probe by replacing traditional gold with an aluminum‐based Ti/Al/Ni multilayer stack. Optimizing this metal architecture suppressed oxidation and ensured robust electrical stability, achieving signal quality comparable to standard gold probes. It enables a highly accessible and economical solution for
Sehwan Park   +6 more
wiley   +1 more source

Coronavirus disease 2019 (COVID-19) : update and information for long-term care facilities [PDF]

open access: yes
Date: Tuesday, March 17, 2020Time: 2:00 P.M. \u2013 3:00P.M. (Eastern Time)During this COCA Call, presenters will focus on current information about COVID-19 as it relates to long-term care facilities, including nursing homes.

core  

Home - About - Disclaimer - Privacy